Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Triple Negative Breast Cancer Clinical Trials

11 recruiting trials for Triple Negative Breast Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
11
Total Trials
11
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 2NCT03808337

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for...

This study is being done to determine if stereotactic body radiotherapy (SBRT) when delivered to all sites of disease in participants with 1-5 metastases will increase the length...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 14512 locations
RECRUITINGNCT06371274

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

To evaluate the clinical efficacy and safety of oral all-trans retinoic acid in combination with toripalimab in patients with locally advanced, recurrent, or metastatic...

Sponsor: First Affiliated Hospital of Zhejiang UniversityEnrolling: 291 location
RECRUITINGPhase 2NCT04159142

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative...

This is a multi-center , open-lable clinical trial. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have \<1% expression of the estrogen...

Sponsor: Hebei Medical University Fourth HospitalEnrolling: 4141 location
RECRUITINGPhase 1 / Phase 2NCT04787042

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab...

Sponsor: Simcha IL-18, Inc.Enrolling: 3166 locations
RECRUITINGNCT06328465

fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases

The aim of this study is to understand whether DWB-MRI (Diffusion Whole Body-Magnetic Resonance Imaging) is useful for early detection of locoregional or distant recurrence and...

Sponsor: European Institute of OncologyEnrolling: 1451 location
RECRUITINGPhase 1NCT06451497

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With...

This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have...

Sponsor: Zumutor Biologics Inc.Enrolling: 1003 locations
RECRUITINGPhase 1 / Phase 2NCT05086692

A Beta-only IL-2 ImmunoTherapY Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor...

Sponsor: Medicenna Therapeutics, Inc.Enrolling: 11520 locations
RECRUITINGPhase 1 / Phase 2NCT06682793

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid...

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung...

Sponsor: A2 Biotherapeutics Inc.Enrolling: 24010 locations
RECRUITINGPhase 1NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and...

Sponsor: SystImmune Inc.Enrolling: 47020 locations
RECRUITINGPhase 1NCT05627960

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal...

Sponsor: A&G Pharmaceutical Inc.Enrolling: 771 location
RECRUITINGPhase 1 / Phase 2NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid...

Sponsor: GenmabEnrolling: 76420 locations